Cervical cancer (CC) is the fourth most common cancer in women worldwide, strongly linked to high-risk human papilloma virus infection. In high-income countries, the screening programs have dramatically decreased the incidence of CC; however, the lack of accessibility to them in developing countries makes CC an important cause of mortality. Clinical stage is the most relevant prognostic factor in CC. The new FIGO staging system published in 2018 is more accurate than the previous one since it takes into account the lymph node status. In early stages, the primary treatment is surgery—with some concerns recently raised regarding minimally invasive surgery because it might decrease survival—or radiotherapy, whereas concomitant chemo-radiotherapy is the conventional approach in locally advanced stages. For recurrent or metastatic CC, the combination of chemotherapy plus bevacizumab is the preferred therapy. Immunotherapy approach based on checkpoint inhibitors is evolving as the election therapy following failure to platinum therapy.
Cervical cancer; Staging; Treatment
de Juan A, Redondo A, Rubio MJ, García Y, Cueva J, Gaba L, et al. SEOM clinical guidelines for cervical cancer (2019). Clin Transl Oncol. 2020 Feb;22:270-8.
Use this identifier for quote and/or link this documenthttps://hdl.handle.net/11351/6323
The following license files are associated with this item: